Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

The incidence and prevalence of inflammatory bowel disease (IBD) are increasing worldwide. Current approved medication for IBD treatment in the clinic mainly includes corticosteroids and neutralization antibodies to pro-inflammatory cytokines. However, drug resistance and severe side effect hinder l...

Full description

Bibliographic Details
Main Authors: Qiu-Ling Chen, Hao-Ran Yin, Qing-Yu He, Ying Wang
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
NLRP3
Inflammatory bowel disease
Small molecule inhibitor
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221002274

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221002274

Similar Items